The Experts below are selected from a list of 3210 Experts worldwide ranked by ideXlab platform

Carl-gerhard Gottfries - One of the best experts on this subject based on the ideXlab platform.

  • Long-Term Treatment with a Staphylococcus Toxoid Vaccine in Patients with Fibromyalgia and Chronic Fatigue Syndrome
    Journal of Chronic Fatigue Syndrome, 2006
    Co-Authors: Carl-gerhard Gottfries, Björn Regland, Ove Häger, Olof Zachrisson
    Abstract:

    AbstractOne hundred and sixty patients with fibromyalgia and chronic fatigue syndrome, who were on a continuous treatment with a Staphylococcus Vaccine, were followed during one year with repeated consultation visits. The patients had participated in controlled studies and been on continuous treatment with the Vaccine for 22±10 months before inclusion into this follow-up study. They were treated with 1 mL of the Vaccine subcutaneously every third to fourth week. Adverse events were few. The adherence to the treatment was very good. Over a period of one year, 8% withdrew, and in only 5%, the withdrawal was due to insufficient clinical effect. Only in two cases where the patients were allergic to the preservative of the Vaccine, the side effects caused the withdrawal of the treatment. Ratings with scales (CPRS-15 and FibroFatigue) showed improvement from start of treatment and also further improvement during the follow-up year. In view of the natural history for these disorders the result is of interest.

  • Nickel Allergy Is Found in a Majority of Women with Chronic Fatigue Syndrome and Muscle Pain- And May Be Triggered by Cigarette Smoke and Dietary Nickel Intake
    Journal of Chronic Fatigue Syndrome, 2001
    Co-Authors: Björn Regland, Olof Zachrisson, Vera Stejskal, Carl-gerhard Gottfries
    Abstract:

    ABSTRACTTwo hundred and four women with chronic fatigue and muscle pain, with no signs of autoimmune disorder, received immune stimulation injections with a Staphylococcus Vaccine at monthly intervals over 6 months. Good response was defined as a decrease by at least 50% of the total score on an observer's rating scale. Nickel allergy was evaluated as probable if the patient had a positive history of skin hyper-sensitivity from cutaneous exposure to metal objects. The patient's smoking habits were recorded. Fifty-two percent of the patients had a positive history of nickel contact dermatitis. There were significantly more good responders among the non-allergic non-smokers (39%) than among the allergic smokers (6%). We also present case reports on nickel-allergic patients who apparently improved after cessation of cigarette smoking and reducing their dietary nickel intake. Our observations indicate that exposure to nickel, by dietary intake or inhalation of cigarette smoke, may trigger systemic nickel alle...

Olof Zachrisson - One of the best experts on this subject based on the ideXlab platform.

  • Long-Term Treatment with a Staphylococcus Toxoid Vaccine in Patients with Fibromyalgia and Chronic Fatigue Syndrome
    Journal of Chronic Fatigue Syndrome, 2006
    Co-Authors: Carl-gerhard Gottfries, Björn Regland, Ove Häger, Olof Zachrisson
    Abstract:

    AbstractOne hundred and sixty patients with fibromyalgia and chronic fatigue syndrome, who were on a continuous treatment with a Staphylococcus Vaccine, were followed during one year with repeated consultation visits. The patients had participated in controlled studies and been on continuous treatment with the Vaccine for 22±10 months before inclusion into this follow-up study. They were treated with 1 mL of the Vaccine subcutaneously every third to fourth week. Adverse events were few. The adherence to the treatment was very good. Over a period of one year, 8% withdrew, and in only 5%, the withdrawal was due to insufficient clinical effect. Only in two cases where the patients were allergic to the preservative of the Vaccine, the side effects caused the withdrawal of the treatment. Ratings with scales (CPRS-15 and FibroFatigue) showed improvement from start of treatment and also further improvement during the follow-up year. In view of the natural history for these disorders the result is of interest.

  • Nickel Allergy Is Found in a Majority of Women with Chronic Fatigue Syndrome and Muscle Pain- And May Be Triggered by Cigarette Smoke and Dietary Nickel Intake
    Journal of Chronic Fatigue Syndrome, 2001
    Co-Authors: Björn Regland, Olof Zachrisson, Vera Stejskal, Carl-gerhard Gottfries
    Abstract:

    ABSTRACTTwo hundred and four women with chronic fatigue and muscle pain, with no signs of autoimmune disorder, received immune stimulation injections with a Staphylococcus Vaccine at monthly intervals over 6 months. Good response was defined as a decrease by at least 50% of the total score on an observer's rating scale. Nickel allergy was evaluated as probable if the patient had a positive history of skin hyper-sensitivity from cutaneous exposure to metal objects. The patient's smoking habits were recorded. Fifty-two percent of the patients had a positive history of nickel contact dermatitis. There were significantly more good responders among the non-allergic non-smokers (39%) than among the allergic smokers (6%). We also present case reports on nickel-allergic patients who apparently improved after cessation of cigarette smoking and reducing their dietary nickel intake. Our observations indicate that exposure to nickel, by dietary intake or inhalation of cigarette smoke, may trigger systemic nickel alle...

Björn Regland - One of the best experts on this subject based on the ideXlab platform.

  • Long-Term Treatment with a Staphylococcus Toxoid Vaccine in Patients with Fibromyalgia and Chronic Fatigue Syndrome
    Journal of Chronic Fatigue Syndrome, 2006
    Co-Authors: Carl-gerhard Gottfries, Björn Regland, Ove Häger, Olof Zachrisson
    Abstract:

    AbstractOne hundred and sixty patients with fibromyalgia and chronic fatigue syndrome, who were on a continuous treatment with a Staphylococcus Vaccine, were followed during one year with repeated consultation visits. The patients had participated in controlled studies and been on continuous treatment with the Vaccine for 22±10 months before inclusion into this follow-up study. They were treated with 1 mL of the Vaccine subcutaneously every third to fourth week. Adverse events were few. The adherence to the treatment was very good. Over a period of one year, 8% withdrew, and in only 5%, the withdrawal was due to insufficient clinical effect. Only in two cases where the patients were allergic to the preservative of the Vaccine, the side effects caused the withdrawal of the treatment. Ratings with scales (CPRS-15 and FibroFatigue) showed improvement from start of treatment and also further improvement during the follow-up year. In view of the natural history for these disorders the result is of interest.

  • Nickel Allergy Is Found in a Majority of Women with Chronic Fatigue Syndrome and Muscle Pain- And May Be Triggered by Cigarette Smoke and Dietary Nickel Intake
    Journal of Chronic Fatigue Syndrome, 2001
    Co-Authors: Björn Regland, Olof Zachrisson, Vera Stejskal, Carl-gerhard Gottfries
    Abstract:

    ABSTRACTTwo hundred and four women with chronic fatigue and muscle pain, with no signs of autoimmune disorder, received immune stimulation injections with a Staphylococcus Vaccine at monthly intervals over 6 months. Good response was defined as a decrease by at least 50% of the total score on an observer's rating scale. Nickel allergy was evaluated as probable if the patient had a positive history of skin hyper-sensitivity from cutaneous exposure to metal objects. The patient's smoking habits were recorded. Fifty-two percent of the patients had a positive history of nickel contact dermatitis. There were significantly more good responders among the non-allergic non-smokers (39%) than among the allergic smokers (6%). We also present case reports on nickel-allergic patients who apparently improved after cessation of cigarette smoking and reducing their dietary nickel intake. Our observations indicate that exposure to nickel, by dietary intake or inhalation of cigarette smoke, may trigger systemic nickel alle...

Ove Häger - One of the best experts on this subject based on the ideXlab platform.

  • Long-Term Treatment with a Staphylococcus Toxoid Vaccine in Patients with Fibromyalgia and Chronic Fatigue Syndrome
    Journal of Chronic Fatigue Syndrome, 2006
    Co-Authors: Carl-gerhard Gottfries, Björn Regland, Ove Häger, Olof Zachrisson
    Abstract:

    AbstractOne hundred and sixty patients with fibromyalgia and chronic fatigue syndrome, who were on a continuous treatment with a Staphylococcus Vaccine, were followed during one year with repeated consultation visits. The patients had participated in controlled studies and been on continuous treatment with the Vaccine for 22±10 months before inclusion into this follow-up study. They were treated with 1 mL of the Vaccine subcutaneously every third to fourth week. Adverse events were few. The adherence to the treatment was very good. Over a period of one year, 8% withdrew, and in only 5%, the withdrawal was due to insufficient clinical effect. Only in two cases where the patients were allergic to the preservative of the Vaccine, the side effects caused the withdrawal of the treatment. Ratings with scales (CPRS-15 and FibroFatigue) showed improvement from start of treatment and also further improvement during the follow-up year. In view of the natural history for these disorders the result is of interest.

Edo SEGAL - One of the best experts on this subject based on the ideXlab platform.

  • Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis
    Vaccines for Invasive Fungal Infections, 2017
    Co-Authors: Edo SEGAL
    Abstract:

    The following article will concentrate on the NDV-3 anti-Candida and Staphylococcus Vaccine. The Vaccine is composed of the N-terminal portion of the Candida albicans agglutinin-like sequence 3 protein (Als3p) and aluminum hydroxide as adjuvant. The Vaccine conferred protection to mice against experimental vaginal, oral, and intravenous challenge with C. albicans. Due to the sequence and structural homology of the Als3p with Staphylococcus aureus surface proteins, the Vaccine also protected against experimental skin and IV infection with S. aureus. The Vaccine has reached the stage of human trials: phase 1 clinical studies have shown that the Vaccine is safe and immunogenic. The latest brief conference abstract reports of vaccination in women suffering from recurrent vaginal candidiasis, indicating that the recurrence rates were lower in the women receiving the Vaccine.